SCHEMBL5535853

SCHEMBL5535853

COc1ccc(-c2ccc3s[c]nc3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.43
DYRK1A Q13627 2/20 0.42
ABL1 P00519 2/20 0.41
ABCB1 P08183 1/20 0.41
BCR P11274 1/20 0.41
MAP4K4 O95819 1/20 0.40
NT5E P21589 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540744 0.87 ABL1 (0.44) KDRDYRK1AABL1ABCB1BCR
SCHEMBL2160767 0.86 RAB9A (0.43) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL5541045 0.81 PIK3CA (0.42) KDRMAP4K4ALDH1A1L3MBTL1
SCHEMBL533470 0.76 CYP1A2 (0.49) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL482247 0.72 ALDH1A1 (0.45) NPC1RAB9ASMN1; SMN2TP53KDM4E
SCHEMBL9191661 0.72 FFAR1 (0.48) KDRDYRK1AABL1ABCB1BCR
SCHEMBL13862772 0.71 ALDH1A1 (0.51) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL1832902 0.70 MAPT (0.38) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL12639217 0.69 SMN1; SMN2 (0.71) DYRK1ANPC1RAB9ASMN1; SMN2TP53
SCHEMBL5535527 0.69 ABL1 (0.42) ABL1ABCB1BCRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDR 3886/4885DYRK1A 2922/4885ABL1 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.